Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy

NCT02327923 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-11-30

No results posted yet for this study

Summary

Comparison of intraoperative infusion of lidocaine and esmolol in the postoperative requirement of opioid for postoperative pain management after laparoscopic cholecystectomy to decrease opioid related side effects and enhance postoperative recovery with multimodal analgesia approach.

Conditions

  • Gall Stone Disease

Interventions

DRUG

Lidocaine

Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.

DRUG

Esmolol

Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.

DRUG

Paracetamol

Inj. Paracetamol 1 gm IV at the time of induction

DRUG

Lidocaine

Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.

DRUG

Propofol

Inj. Propofol 2- 2.5 mg/kg will be given for induction

DRUG

Fentanyl

Inj fentanyl 1.5mg/kg will be given at the time of induction.

DRUG

Vecuronium

Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.

DRUG

Atropine

Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)

DRUG

Ephedrine

DRUG

Morphine

DRUG

Ketorolac

DRUG

Ondansetron

DRUG

Bupivacaine

Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.

DRUG

Tramadol

Inj tramadol 50 mg IV will be given on SOS basis in ward.

DRUG

Neostigmine

50 mcg/kg for reversal of residual neuromuscular blockade

DRUG

Glycopyrrolate

10 mcg/kg with neostigmine

Sponsors & Collaborators

  • B.P. Koirala Institute of Health Sciences

    lead OTHER

Principal Investigators

  • Asish Subedi, MD · B.P. Koirala Institute of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-02-29
Completion
2016-04-30

Countries

  • Nepal

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327923 on ClinicalTrials.gov